Overview

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
Rampart Health, L.L.C.
Treatments:
Cyclophosphamide
Ipilimumab
Pembrolizumab
Sargramostim